Stopping unnecessary heart medications in older adults with Alzheimer's disease and related dementias
Deprescribing Cardiovascular Medications among Persons with and without Alzheimer's Disease and Related Dementias in Long-Term Care
This study is looking at whether stopping certain heart medications is safe and helpful for older nursing home residents with Alzheimer's and similar conditions, to see if it can improve their health and well-being.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Palo Alto Veterans Instit for Research NIH-funded |
| Lab location | 1 site (Palo Alto, United States) |
| Project ID | NIH-11125213 on NIH RePORTER |
What this research studies
This research investigates the process of deprescribing cardiovascular medications in nursing home residents, particularly those with Alzheimer's disease and related dementias. It aims to determine the effects and benefits of stopping these medications, which may pose more risks than benefits for this population. By analyzing a large cohort of approximately 150,000 residents aged 65 and older in Veteran's Health Administration nursing homes, the study seeks to provide evidence on which patients could safely discontinue these medications. The approach includes evaluating the health outcomes of residents before and after deprescribing.
Who could benefit from this research
Good fit: Ideal candidates for this research are nursing home residents aged 65 and older, particularly those diagnosed with Alzheimer's disease or related dementias.
Not a fit: Patients who are younger than 65 or do not have Alzheimer's disease or related dementias may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer medication practices and improved quality of life for older adults with Alzheimer's disease and related dementias.
How similar studies have performed: While many studies have focused on starting cardiovascular medications, few have explored the effects of deprescribing, making this research a novel approach.
Where this research is happening
Palo Alto, United States
- Palo Alto Veterans Instit for Research — Palo Alto, United States (Active)
Researchers
- Principal investigator: Odden, Michelle Christina — Palo Alto Veterans Instit for Research
- Study coordinator: Odden, Michelle Christina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.